vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Hyperscale Data, Inc. (GPUS). Click either name above to swap in a different company.
Hyperscale Data, Inc. is the larger business by last-quarter revenue ($26.9M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -112.0%, a 111.1% gap on every dollar of revenue. On growth, Hyperscale Data, Inc. posted the faster year-over-year revenue change (38.4% vs -25.7%). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-56.2M). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -16.3%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Hyperscale Data, Inc. provides GPU-accelerated computing infrastructure and cloud solutions tailored for AI development, big data processing, and high-performance computing workloads. It primarily serves AI startups, large technology firms, and cloud service providers across North America and the Asia-Pacific region, delivering scalable, high-efficiency computing resources to support complex data processing needs.
CTMX vs GPUS — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $26.9M |
| Net Profit | $-154.0K | $-30.1M |
| Gross Margin | — | 14.5% |
| Operating Margin | -6.9% | -117.8% |
| Net Margin | -0.8% | -112.0% |
| Revenue YoY | -25.7% | 38.4% |
| Net Profit YoY | 97.6% | -6670.3% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $26.9M | ||
| Q3 25 | — | $24.3M | ||
| Q2 25 | $18.7M | $25.9M | ||
| Q1 25 | $50.9M | $25.0M | ||
| Q4 24 | $38.1M | $19.4M | ||
| Q3 24 | $33.4M | $31.1M | ||
| Q2 24 | $25.1M | $17.8M | ||
| Q1 24 | $41.5M | $38.4M |
| Q4 25 | — | $-30.1M | ||
| Q3 25 | — | $-13.0M | ||
| Q2 25 | $-154.0K | $-19.1M | ||
| Q1 25 | $23.5M | $-4.2M | ||
| Q4 24 | $18.9M | $-445.0K | ||
| Q3 24 | $5.7M | $-25.5M | ||
| Q2 24 | $-6.5M | $-33.9M | ||
| Q1 24 | $13.8M | $3.7M |
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 25.8% | ||
| Q2 25 | — | 23.7% | ||
| Q1 25 | — | 21.1% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | 27.5% | ||
| Q2 24 | — | -21.3% | ||
| Q1 24 | — | 47.4% |
| Q4 25 | — | -117.8% | ||
| Q3 25 | — | -57.8% | ||
| Q2 25 | -6.9% | -39.2% | ||
| Q1 25 | 44.4% | -25.5% | ||
| Q4 24 | 46.4% | -46.8% | ||
| Q3 24 | 12.3% | -79.2% | ||
| Q2 24 | -33.7% | -151.4% | ||
| Q1 24 | 28.1% | 9.5% |
| Q4 25 | — | -112.0% | ||
| Q3 25 | — | -53.5% | ||
| Q2 25 | -0.8% | -73.7% | ||
| Q1 25 | 46.2% | -16.8% | ||
| Q4 24 | 49.6% | -2.3% | ||
| Q3 24 | 17.2% | -82.3% | ||
| Q2 24 | -26.0% | -190.7% | ||
| Q1 24 | 33.3% | 9.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.39 | ||
| Q2 25 | — | $-2.66 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-8.78 | ||
| Q3 24 | — | $-24.82 | ||
| Q2 24 | — | $-37.81 | ||
| Q1 24 | — | $3.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $13.1M |
| Total DebtLower is stronger | — | $83.1M |
| Stockholders' EquityBook value | $119.9M | $119.8M |
| Total Assets | $175.1M | $313.7M |
| Debt / EquityLower = less leverage | — | 0.69× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $24.8M | ||
| Q2 25 | $49.0M | $5.9M | ||
| Q1 25 | $47.6M | $4.2M | ||
| Q4 24 | $38.1M | $4.5M | ||
| Q3 24 | $40.6M | $7.9M | ||
| Q2 24 | $43.2M | $9.6M | ||
| Q1 24 | $36.2M | $18.9M |
| Q4 25 | — | $83.1M | ||
| Q3 25 | — | $80.0M | ||
| Q2 25 | — | $88.5M | ||
| Q1 25 | — | $92.8M | ||
| Q4 24 | — | $96.7M | ||
| Q3 24 | — | $104.8M | ||
| Q2 24 | — | $106.8M | ||
| Q1 24 | — | $30.0M |
| Q4 25 | — | $119.8M | ||
| Q3 25 | — | $55.9M | ||
| Q2 25 | $119.9M | $5.5M | ||
| Q1 25 | $25.0M | $6.3M | ||
| Q4 24 | $-456.0K | $8.6M | ||
| Q3 24 | $-23.5M | $2.7M | ||
| Q2 24 | $-31.2M | $26.7M | ||
| Q1 24 | $-31.7M | $59.0M |
| Q4 25 | — | $313.7M | ||
| Q3 25 | — | $242.4M | ||
| Q2 25 | $175.1M | $213.5M | ||
| Q1 25 | $98.5M | $218.5M | ||
| Q4 24 | $120.5M | $220.8M | ||
| Q3 24 | $139.0M | $231.5M | ||
| Q2 24 | $159.2M | $270.8M | ||
| Q1 24 | $184.7M | $299.8M |
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 16.06× | ||
| Q1 25 | — | 14.71× | ||
| Q4 24 | — | 11.19× | ||
| Q3 24 | — | 38.41× | ||
| Q2 24 | — | 4.00× | ||
| Q1 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-37.7M |
| Free Cash FlowOCF − Capex | $-15.8M | $-56.2M |
| FCF MarginFCF / Revenue | -84.6% | -208.7% |
| Capex IntensityCapex / Revenue | 0.1% | 68.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-87.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-37.7M | ||
| Q3 25 | — | $-17.8M | ||
| Q2 25 | $-15.8M | $-3.1M | ||
| Q1 25 | $-21.0M | $-4.0M | ||
| Q4 24 | $-19.9M | $-9.2M | ||
| Q3 24 | $-20.7M | $3.7M | ||
| Q2 24 | $-19.5M | $-3.7M | ||
| Q1 24 | $-26.0M | $-10.2M |
| Q4 25 | — | $-56.2M | ||
| Q3 25 | — | $-20.6M | ||
| Q2 25 | $-15.8M | $-3.5M | ||
| Q1 25 | $-21.2M | $-6.8M | ||
| Q4 24 | $-20.0M | $-9.3M | ||
| Q3 24 | $-20.7M | $2.6M | ||
| Q2 24 | $-19.6M | $-5.9M | ||
| Q1 24 | $-26.2M | $-11.6M |
| Q4 25 | — | -208.7% | ||
| Q3 25 | — | -84.5% | ||
| Q2 25 | -84.6% | -13.5% | ||
| Q1 25 | -41.6% | -27.3% | ||
| Q4 24 | -52.5% | -47.6% | ||
| Q3 24 | -62.1% | 8.4% | ||
| Q2 24 | -78.2% | -33.4% | ||
| Q1 24 | -63.1% | -30.3% |
| Q4 25 | — | 68.6% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.2% | 11.5% | ||
| Q4 24 | 0.2% | 0.3% | ||
| Q3 24 | 0.1% | 3.6% | ||
| Q2 24 | 0.4% | 12.6% | ||
| Q1 24 | 0.3% | 3.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | -2.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
GPUS
| Transferred Over Time | $10.4M | 39% |
| Revenue From Mined Crypto Assets At Sentinum Owned And Operated Facilities | $5.8M | 21% |
| Hotel And Real Estate Operations | $4.8M | 18% |
| Other | $4.0M | 15% |
| Turn On Green | $2.0M | 7% |
